BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24279123)

  • 21. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detectability of hepatocellular carcinoma by gadoxetate disodium-enhanced hepatic MRI: tumor-by-tumor analysis in explant livers.
    Nakamura Y; Tashiro H; Nambu J; Ohdan H; Kakizawa H; Date S; Awai K
    J Magn Reson Imaging; 2013 Mar; 37(3):684-91. PubMed ID: 23055436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.
    Galia M; Agnello F; Sparacia G; Matranga D; Albano D; Midiri M; Lagalla R
    Radiol Med; 2018 Jul; 123(7):489-497. PubMed ID: 29546493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease.
    Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK
    Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using low tube voltage (80kVp) quadruple phase liver CT for the detection of hepatocellular carcinoma: two-year experience and comparison with Gd-EOB-DTPA enhanced liver MRI.
    Lee CH; Kim KA; Lee J; Park YS; Choi JW; Park CM
    Eur J Radiol; 2012 Apr; 81(4):e605-11. PubMed ID: 22297180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in the Diagnosis and Treatment of Patients with Early-Stage Hepatocellular Liver Cancer by Multi-Row Spiral CTMDCT and Gd-EOB-DTPA-Enhanced MRI.
    Wang K; Jin X; Zhou J; Wang Z; Zhang X
    Altern Ther Health Med; 2024 Jan; 30(1):31-35. PubMed ID: 37773658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
    Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different signal intensity at Gd-EOB-DTPA compared with Gd-DTPA-enhanced MRI in hepatocellular carcinoma transgenic mouse model in delayed phase hepatobiliary imaging.
    Korkusuz H; Knau LL; Kromen W; Bihrer V; Keese D; Piiper A; Vogl TJ
    J Magn Reson Imaging; 2012 Jun; 35(6):1397-402. PubMed ID: 22267126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of Gd-EOB-DTPA-Enhanced MRI and Diffusion-Weighted Imaging in Detecting Residual Hepatocellular Carcinoma After Drug-Eluting Bead Transarterial Chemoembolization.
    Liu HF; Xu YS; Liu Z; Che KY; Sheng Y; Ding JL; Zhang JG; Lei JQ; Xing W
    Acad Radiol; 2021 Jun; 28(6):790-798. PubMed ID: 32414638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HCC-to-liver contrast on arterial-dominant phase images of EOB-enhanced MRI: comparison with dynamic CT.
    Kanata N; Yoshikawa T; Ohno Y; Kanda T; Uchida K; Izaki K; Fukumoto T; Ku Y; Itoh T; Kitajima K; Takahashi S; Sugimura K
    Magn Reson Imaging; 2013 Jan; 31(1):17-22. PubMed ID: 22898685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics.
    Choi JY; Kim MJ; Park YN; Lee JM; Yoo SK; Rha SY; Seok JY
    AJR Am J Roentgenol; 2011 Aug; 197(2):399-405. PubMed ID: 21785086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of combination of imaging modalities in the diagnosis of hepatocellular carcinoma using Sonazoid®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomography.
    Alaboudy A; Inoue T; Hatanaka K; Chung H; Hyodo T; Kumano S; Murakami T; Moustafa EF; Kudo M
    Oncology; 2011; 81 Suppl 1():66-72. PubMed ID: 22212939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study.
    Ichikawa S; Motosugi U; Morisaka H; Kozaka K; Goshima S; Ichikawa T
    Magn Reson Med Sci; 2021 Mar; 20(1):47-59. PubMed ID: 32101818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging.
    Okada M; Imai Y; Kim T; Kogita S; Takamura M; Kumano S; Onishi H; Hori M; Fukuda K; Hayashi N; Wakasa K; Sakamoto M; Murakami T
    J Magn Reson Imaging; 2010 Oct; 32(4):903-13. PubMed ID: 20882621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy response assessment after radioembolization of patients with hepatocellular carcinoma--comparison of MR imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid and gadobutrol.
    Schelhorn J; Best J; Reinboldt MP; Gerken G; Ruhlmann M; Lauenstein TC; Antoch G; Kinner S
    J Vasc Interv Radiol; 2015 Jul; 26(7):972-9. PubMed ID: 25937296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of recurrent hepatocellular carcinoma on post-operative surveillance: comparison of MDCT and gadoxetic acid-enhanced MRI.
    Kim KA; Kim MJ; Choi JY; Park MS; Lim JS; Chung YE; Kim KW
    Abdom Imaging; 2014 Apr; 39(2):291-9. PubMed ID: 24384804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.